Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review

Breast cancer is the global leading cause of cancer-related death in women and it represents a major health burden worldwide. One of the promising breast cancer therapeutic avenues is through small molecule inhibitors (SMIs) which have undergone rapid progress with successful clinical trials. Recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Nur Husna, Siti Muhamad, Tan, Hern-Tze Tina, Mohamud, Rohimah, Dyhl-Polk, Anne, Wong, Kah Keng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236629/
https://www.ncbi.nlm.nih.gov/pubmed/30542378
http://dx.doi.org/10.1177/1758835918808509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236629/
https://www.ncbi.nlm.nih.gov/pubmed/30542378
http://dx.doi.org/10.1177/1758835918808509

Ejemplares similares